Posted by ABMN Staff on Feb 6th, 2026
AbbVie (NYSE:ABBV) executives said the company closed 2025 with record revenue and earnings above initial expectations, citing strong performance from its “ex-Humira growth platform,” continued momentum for Skyrizi and Rinvoq,...
More of this article »